Recruiting

Pulmonary Artery Catheter

Sponsor:

Tufts Medical Center

Code:

NCT05485376

Conditions

Cardiogenic Shock

Heart Failure

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Pulmonary Artery Catheter

Study Details

Brief summary:

The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.

Conditions

Cardiogenic Shock

Heart Failure

Study ID

NCT05485376

Start date

Aug 23, 2022

Status verified date

Oct, 2025

Completion date

Sep 1, 2026

Anticipated

Primary completion date

Sep 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age ≥18 years and ≤90 years
2. Clinical heart failure presentation and left ventricular function as follows: Either 2A or 2B must be present A. Subject has de novo acute decompensated heart failure and shock with an LVEF ≤40% OR B. Subject has acute on chronic heart failure with a documented history of a LVEF ≤40% within 6 months of admission and a current LVEF ≤40% within 24 hours of screening during the current hospitalization.

NOTE: The LVEF must be quantitatively measured as ≤ 40% by an echocardiogram within 24 hours of screening. If multiple echocardiograms have been performed within 24 hours, the most recent test must be used to qualify the patient.
3. Cardiogenic Shock (CS) defined by a lactate level ≥ 2.1 mmol/L and any 2 of the following parameters within 24 hours of screening:

1. SBP <90 mmHg for more than 30 minutes from baseline SBP
2. Requires the use of at least 1 vasopressor or inotrope
3. Requires intra-aortic balloon pump (IABP) support
4. Presence of congestion on exam: JVP elevated, pulmonary edema on CXR or exam, dyspnea at rest, orthopnea, bendopnea, or worsening peripheral or abdominal swelling
4. Initial diagnosis of CS within 24 hours of screening at the enrolling site
5. Patient or legally authorized representative provides informed consent

A HIPAA waiver for screening is requested to identify potential subjects. No recruitment materials will be given to potential subjects. No identifiable data will be retained for subjects that are determined to be ineligible

Exclusion Criteria:

1. Primary etiology of shock other than systolic left heart failure including but not limited to: acute myocardial infarction, sepsis, hypovolemia, hemorrhage, severe anemia, primary RV failure, pulmonary embolism, or tamponade.
2. Patient has a durable ventricular assist device or temporary mechanical circulatory support (other than IABP) or PAC prior to enrollment
3. Actively listed for cardiac transplantation (Status 7 patients are eligible for the trial)
4. Patient transferred from another facility with a diagnosis of cardiogenic shock
5. Any known co-morbidity other than heart failure with anticipated survival < 6 months
6. Pre-enrollment labs (any of the following): International Normalized Ratio (INR) > 3, Platelet count < 50k, Hemoglobin < 7
7. Refractory or recurrent cardiac arrest (>1 episode requiring defibrillation or cardiopulmonary resuscitation) within 24 hours prior to screening
8. DNR/ DNI status
9. Pregnancy, child-birth within 6 months, or lactation
10. Active infection documented by persistent fever (Temp > 38.4oC within 24 hours of screening) or confirmed bacteremia
11. Implantation of PPM or ICD within past 3 months
12. Mechanical complication of AMI (ie VSD, papillary muscle rupture, flail mitral regurgitation, free wall rupture)
13. Anoxic brain injury
14. On renal replacement therapy prior to enrollment
15. Cardiac surgery within 3 months of current admission
16. Severe aortic, pulmonic, tricuspid stenosis or acute structural mitral regurgitation or infective endocarditis
17. History of cardiac amyloid
18. Congenital heart disease excluding the presence of a bicuspid aortic valve
19. Planned cardiac surgery during admission
20. World Health Organization (WHO) Group I, III, IV, or V pulmonary hypertension
21. Any known contraindication to PAC placement
22. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint
23. Any medical or psychiatric condition such as dementia, alcoholism, or substance abuse which may preclude informed consent or interfere with any of the study procedures, including follow-up
24. Prior stroke with any permanent neurologic deficit or any prior intracranial hemorrhage or any prior subdural hematoma or known intracranial pathology pre-disposing to intracranial bleeding, such as an arteriovenous malformation or mass
25. Subject has previously hospitalized for COVID-19 unless he/she has been discharged and asymptomatic for ≥4 weeks
26. Subject is COVID-19 PCR/antigen positive within the prior 4 weeks
27. Subject belongs to a vulnerable population \[defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, members of the armed forces and persons kept in detention\]

Study Design

Enrollment

400 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Early Pulmonary Artery Catheter

If you are in the experimental group a PAC will be placed within 6 hours of randomization and within 24 hours of presentation with ADHF-CS.

no intervention: No or delayed Pulmonary Artery Catheter

If you are in the control group, a PAC will not be placed during hospitalization or may be placed 48 hours after randomization into the study. Placement of a PAC within 48 hours is only permitted for emergencies.

Interventions

Pulmonary Artery Catheter

The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.

Primary outcome measure

  • Number of participants who die in the hospital [ Time Frame: Length of stay in hospital, an average of 30 days ]

Central Contacts and Locations

Locations

Tufts Medical Center

Recruiting

Boston, Massachusetts, United States, 02111

Contacts

Principal Investigator:

Haval Chweich, MD

More Information

Sponsor

Tufts Medical Center

Last update posted

Oct 29, 2025

Last verified

Oct, 2025

Keywords

  • Pulmonary Artery Catheter

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Tufts Medical Center on 2025-10-29.